Cannabis Product Liability and Insurance for Clinicians

Professional Indemnity for Medical Cannabis Prescribers

• All clinicians prescribing cannabis in the UK require professional indemnity insurance
• Standard MDU or MPS policies may not automatically cover medical cannabis prescribing
• Clinicians should verify in writing that their indemnity cover extends to cannabis prescribing
• Some specialist insurers have developed policies specifically for medical cannabis practitioners

Professional indemnity insurance is a fundamental requirement for any clinician prescribing in the UK, and medical cannabis prescribing carries specific insurance considerations that practitioners must actively manage. Standard medical defence organisation policies may contain exclusions or limitations relevant to cannabis prescribing, particularly for unlicensed product use. Clinicians should not assume coverage — they should obtain written confirmation that their policy extends to cannabis prescribing activity.

Product Liability in the Cannabis Supply Chain

• Importers and distributors carry product liability exposure for the cannabis products they supply
• Product liability insurance should cover claims arising from product defects or contamination
• Product recall insurance can cover the costs of a controlled drug recall event
• Contractual liability arrangements between supply chain participants affect overall liability exposure

Product liability is a significant risk management consideration for every participant in the medical cannabis supply chain. Importers who supply defective or contaminated products to pharmacies, which in turn dispense them to patients, face complex liability questions that standard commercial insurance may not adequately address. Specialist product liability cover, combined with robust supply chain quality assurance, is the appropriate risk management response.

Clinical Governance and Liability Reduction

• Thorough documentation of prescribing decisions is the most effective liability risk mitigation
• Informed consent processes that explicitly address unlicensed status reduce liability exposure
• Regular clinical review and outcome monitoring demonstrate responsible prescribing practice
• Participation in clinical registries provides evidence of professional engagement with the evidence base

The relationship between clinical governance quality and liability exposure is direct: clinicians who document their prescribing decisions thoroughly, obtain fully informed consent, and review patients regularly are substantially better positioned in the event of a complaint or claim. Medical cannabis clinics should invest in clinical governance infrastructure not only because it improves patient outcomes, but because it provides meaningful protection against the litigation and regulatory risks inherent in prescribing unlicensed medicines.

Insurance Market Developments for the UK Sector

• The UK insurance market for medical cannabis has developed significantly since 2018
• Specialist brokers with cannabis sector expertise can identify appropriate cover more effectively
• Industry bodies are working to support the development of appropriate insurance products
• International insurance experience from Canada and the US is informing UK market development

The UK insurance market for medical cannabis has matured considerably since the 2018 rescheduling, but it remains a specialist area where generic commercial insurance is frequently inadequate. Clinicians, clinics, importers, and pharmacies should work with brokers who have specific cannabis sector experience and who can assess insurance needs across the full range of relevant cover types — professional indemnity, product liability, employers’ liability, and business interruption. The cost of appropriate specialist cover is far outweighed by the risk of operating without it.